Aon Invests in eMed to Expand GLP-1 Population Health Platform
Dublin, Aug. 18, 2025 – Aon plc (NYSE: AON), the global professional services firm, has announced a strategic investment in eMed Population Health, Inc., a fast-growing provider of GLP-1 weight management programs. The move is aimed at expanding employer-sponsored access to GLP-1 therapies and scaling solutions for obesity management.
The decision builds on Aon’s earlier launch of a subsidized GLP-1 weight management benefit program for its U.S. workforce, developed in partnership with eMed. Since its rollout six months ago, the program has attracted more than 1,200 participants, with employees achieving an average weight loss of 22.4 pounds and demonstrating a 95 percent retention rate.
Through this investment, eMed plans to expand the reach of its digital-first healthcare platform, which integrates at-home diagnostics, proctor-led screenings, clinician-guided prescribing, and ongoing adherence support.
Lisa Stevens, Chief Administrative Officer at Aon, emphasized the importance of GLP-1 coverage within the firm’s U.S. Total Rewards strategy.
“When you see the benefits it brings to people you work with every day, it really underscores how the decisions employers make today shape the future health and performance of our workforces and our businesses,” Stevens said.
She added that Aon’s investment in eMed would help create a differentiated global solution focused on medication adherence, reducing long-term healthcare costs while improving employee well-being.
For eMed, the partnership represents a milestone in its mission to deliver sustainable care through an integrated and data-driven approach. Linda Yaccarino, CEO of eMed, described the investment as transformational.
“Our shared vision of market transformation is validated and accelerated by the investment from Aon,” Yaccarino said. “This partnership further enables us to deliver a global solution that helps employers cut health costs and improves quality of life for employees.”
Aon has been expanding its portfolio of GLP-1 solutions and advisory services. Earlier this year, the firm published a multi-year analysis of U.S. commercial health claims data that highlighted the potential of GLP-1 therapies to improve outcomes in obesity management.
Farheen Dam, Head of Health for North America at Aon, said the firm’s advisory teams continue to support employers with tailored GLP-1 strategies.
“The rise of GLP-1 medications and their cost has sparked significant strategic considerations for employers,” Dam noted. “GLP-1s are not a one-size-fits-all solution, which is why we provide data-driven guidance to design strategies that meet the needs of different populations.”
The collaboration underscores how Aon is positioning itself at the intersection of healthcare innovation and workforce strategy, while giving eMed the resources to extend its reach to more employers and patients worldwide.
FAQs on Aon’s Investment in eMed
What is GLP-1 therapy?
GLP-1 therapy uses a class of medications originally developed for diabetes management that has shown significant effectiveness in helping with weight loss and controlling obesity-related health risks.
Why is Aon investing in eMed?
Aon is investing in eMed to scale employer access to GLP-1 solutions, improve medication adherence, and reduce long-term healthcare costs while improving employee well-being.
How has Aon’s workforce program performed so far?
In six months, over 1,200 employees enrolled in Aon’s GLP-1 benefit program. Participants achieved an average of 22.4 pounds in weight loss with a 95% retention rate.
What does eMed’s platform provide?
eMed offers a digital-first healthcare platform that combines at-home testing, clinician-guided prescribing, behavioral support, and continuous monitoring to ensure high adherence and sustainable outcomes.
What does this mean for employers?
The partnership allows employers to access structured, data-driven GLP-1 programs that can improve workforce health, reduce obesity-related costs, and support long-term wellness strategies.
Venkat